Aurinia Pharmaceuticals Overview

  • Founded
  • 1993
Founded
  • Status
  • Public
  • Employees
  • 300
Employees
  • Stock Symbol
  • AUPH
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $11.45
  • (As of Tuesday Closing)

Aurinia Pharmaceuticals General Information

Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.

Contact Information

Formerly Known As
Isotechnika Pharma
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 4464 Markham Street
  • Suite 1203
  • Victoria, British Columbia V8Z 7X8
  • Canada
+1 (250) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aurinia Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.45 $10.99 $8.86 - $33.97 $1.62B 142M 3.01M -$1.28

Aurinia Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 1,296,335 2,688,067 1,359,201 2,060,991
Revenue 66,316 45,605 50,118 318
EBITDA (164,891) (177,974) (102,919) (89,772)
Net Income (168,217) (180,966) (102,680) (88,385)
Total Assets 506,902 543,367 463,661 324,301
Total Debt 8,571 8,739 8,407 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aurinia Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aurinia Pharmaceuticals‘s full profile, request access.

Request a free trial

Aurinia Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious dis
Drug Discovery
Victoria, Canada
300 As of 2021
00000
00000000 00000

000000 0

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Except
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

0000000

oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
000000000000000
Soborg, Denmark
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aurinia Pharmaceuticals Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akebia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
0000000 000000 Formerly VC-backed Soborg, Denmark 000 00000 000000000 00000
000000 000000000 Formerly VC-backed San Francisco, CA 00 00000 000000000 00000
000000000 00000000 Formerly VC-backed Charlottesville, VA 00 000.00 00000000 000.00
00000000000 Corporation Calgary, Canada 00 00000 0000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Aurinia Pharmaceuticals Patents

Aurinia Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190224275-A1 Protocol for treatment of lupus nephritis Pending 12-May-2017 000000000
US-20150202150-A1 Topical drug delivery system for ophthalmic use Abandoned 09-Jun-2009 0000000000 0
ES-2537385-T3 Topical supply systems for ophthalmic use Active 09-Jun-2009 0000000000
US-20100310642-A1 Topical drug delivery systems for ophthalmic use Granted 09-Jun-2009 0000000000 00
CA-2764635-A1 Topical drug delivery systems for ophthalmic use Granted 09-Jun-2009 A61K9/1075
To view Aurinia Pharmaceuticals’s complete patent history, request access »

Aurinia Pharmaceuticals Executive Team (16)

Name Title Board Seat Contact Info
Peter Greenleaf Chief Executive Officer & Board Member
Joseph Miller Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Massimiliano Colao Chief Commercial Officer
Michael Martin Executive
Stephen Robertson Executive Vice President & General Counsel, Legal
You’re viewing 5 of 16 executive team members. Get the full list »

Aurinia Pharmaceuticals Board Members (19)

Name Representing Role Since
00000000 00000000 00.0 Lumira Ventures Board Member 000 0000
000000 000000000000 00.0 Self Board Member 000 0000
000000 000000 00.0 Aurinia Pharmaceuticals Board Member 000 0000
00000 00000 00 Aurinia Pharmaceuticals Board Member 000 0000
000000 00000 00.0 Self Chairman of the Board, Member of Audit Committee and Nominating and Corporate Governance Committee 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Aurinia Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aurinia Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aurinia Pharmaceuticals‘s full profile, request access.

Request a free trial

Aurinia Pharmaceuticals Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 0 01-Jan-2020 0000000000 00000 Drug Discovery 00000 000
Isotechnika Pharma 23-Sep-2013 Merger/Acquisition Biotechnology
To view Aurinia Pharmaceuticals’s complete acquisitions history, request access »